# Brand Research validation

> **Current V2 override — 2 November 2026:** Product Owner rejected A/B/C as current final-direction candidates and authorized exactly D — Precision Health, E — Human Clinical, F — Next-Gen Health OS. [V2 review](visual-directions-v2/README.md) and [verbatim owner request](visual-directions-v2/evidence/owner-request.txt) supersede the older A/B/C labels and visual-quality expectations below. BR01–BR08, accepted UX/IA/content, and approval/implementation boundaries remain binding. No logo, palette, font, UI treatment or direction is selected.

Point-in-time documentation/research evidence, **2 November 2026**. Base: `80cb2bc27d9439f0e57e5bec320ac9bde0121e87`. Authority: [Issue #72 / 6568210676](https://github.com/abuhmaid28/egyhealth360/issues/72#issuecomment-6568210676), checked against the issue and latest applicable owner comments, plus the current explicit Brand Research brief. Six research documents and only necessary status/source/roadmap references form this candidate. No visual design or implementation is authorized.

## Evidence provenance and limits

- Local source/asset evidence is the pinned base. Visually inspected existing BEFORE screenshots: Patient desktop EN/mobile AR, Doctor schedule desktop EN, consultation documentation desktop EN/mobile AR, and login desktop EN. Pharmacy/Admin/Demo audit uses source, not newly executed hosted journeys. Screenshot paths/bytes remain protected.
- Public research: **13 products/services and 5 guidance references**, recorded as R01–R13/G01–G05 in the [reference map](BRAND_REFERENCE_MAP.md). Each has source URL, access date, observation/fact, relevance interpretation and avoid-copy boundary. There are 15 product-page URLs (two bilingual pairs) plus five guidance URLs. No competitor asset is committed.
- Nine public pages yielded meaningful desktop visual evidence; InstaPay yielded only header/identity evidence. Vezeeta's browser request encountered a challenge; Doctolib's browser surface was blank; Sehhaty was text-only. Web-extracted content was available for all included product entries. Altibbi/Fawry/Al Borg attempts were inaccessible/timeout and are excluded from the evidence sample; no conclusions rely on them.
- Temporary browser captures at 1365×950 stayed outside the repository. No login, purchase, clinical mutation or authenticated competitor console/native app was tested. Sources can change after access; a public page is not an independent verification of supplier performance or assurance claims.
- Research is qualitative and purposively sampled. No market-frequency measurement, Egyptian preference survey, Patient/Doctor participant study, native-language certification, trademark clearance, medical readiness claim or new deployment audit is made. FACT/OBSERVATION/INTERPRETATION/RECOMMENDATION are separated; hypotheses remain hypotheses.

## Semantic validation

| Check | Evidence / result |
| --- | --- |
| Product breadth | Strategy and six territories span human-led care across Patient, Doctor, Pharmacy, future Lab and Admin; no booking-only or pharmacy-only positioning |
| Accepted IA | My care / Find care; Schedule / current authorized care; sustained local consultation; secondary source/history retrieval; assigned staff work; operational Admin preserved |
| Accepted CD01–CD07 | Egyptian Arabic and accepted names/numeral/time conventions carried forward; CURRENT_STATUS/source index resolve older adoption-time pending wording; no runtime strings changed |
| Authority/privacy | Booking grants zero clinical authority; current assignment remains clinical grant; staff exact artifact/org/membership; no Admin clinical shortcut, hidden payload/reference/count, universal sharing or permanent author access |
| Clinical consequences | Save/sign/share/close independent; signed prescription, pharmacy acceptance, recorded full-item supply and correction/reversal remain distinct; no medical advice or AI inference |
| Current / future / hosted | Lab and integrated I4 remain future, Demo/Live gaps explicit; no complete-record, emergency-service, hospital-ownership or full production healthcare-readiness claim |
| Research territory neutrality | Six unranked hypotheses; none preselected as A/B/C or treated as owner-approved design |
| Visual choices | No final logo, palette, primary color, hex system, font family, icon library, illustration style, visual winner, mockup or final appearance selected |
| Next-stage contract | Exactly 3 distinct directions; at least 2 materially different logo concepts each / minimum 6 total; rationale for each; equivalent Patient/Doctor UI; A/B/C/HYBRID owner choice; later Final Brand V2 gate |
| Anti-clone / scope | Competitor marks/layouts/whole palettes/distinctive artwork/assets cannot be copied; no frontend/backend/schema/API/test/security/runtime or screenshot changes |

## Technical validation record

Use the repository's actual `scripts/ci/policy.mjs`, `classify.mjs`, `check-docs.mjs` and `gate.mjs`; no substitute CI gate or modified workflow is introduced. Expected path is **DOCS_GOVERNANCE → classify → docs-check → validate**, with heavy lanes skipped by existing policy.

Local checks passed: existing `node --test tests/ci/*.test.mjs` **30/30**; `node scripts/ci/check-docs.mjs` repository sanity/classification/reference checks; `git diff --check` for whitespace. A base-blob comparison verified **597 existing tracked files outside the nine allowed Markdown paths unchanged**, including **all 18 protected doctor-demo files**. No extra untracked files or generated assets were present. The final committed candidate is also checked through the real event-driven classifier/docs checker before push. Exact final head, base, remote run ID/classification/job durations and open/unmerged/auto-merge state belong in the PR handoff so this evidence file does not require a self-referential commit SHA or another CI-triggering evidence-only commit.

## Fresh-agent comprehension

The owner explicitly requested an independent fresh design/product agent test. A separate agent with **no inherited conversation** read AGENTS, current status/charter/source index and the five research/strategy/brief/register documents. It did not read this validation answer record, edit files or create a branch/PR. It independently answered all 20 questions with section citations: **20/20 PASS**. The table records its returned answers in compact form, not a parent-only comprehension simulation.

| # / owner question | Fresh-agent answer / evidence |
| --- | --- |
| 1 What is EgyHealth? | Human-led connected care across Patient, Doctor, Pharmacy, future Lab and operational Admin; synthetic graduation platform with current/future limits. Strategy: Product truth before positioning |
| 2 Patient feeling? | Understand events and next action; respected information; local relevance and understandable modernity. Strategy: Patient and Doctor emotional goals |
| 3 Doctor feeling? | Credible, oriented, clinically respected and efficient through relevant work. Same strategy section |
| 4 Desired attributes? | Clear, credible, human, calm, accountable, locally fluent, accessible/modern, connected with boundaries. Strategy: Desired attributes and anti-attributes |
| 5 Unwanted attributes? | Jargon/overload, bureaucracy, coldness, infantilization, alarmism, magic AI, tourist stereotypes, English-first neglect and generic dashboard decoration. Strategy attributes / BR04 |
| 6 Healthcare clichés? | Qualitative cross/heart/ECG/stethoscope/shield/pill/etc. risk assessment; transformation may permit some symbols, protected emblems and unsupported AI functions excluded. Research: Healthcare logo cliché assessment |
| 7 Egyptian relevance? | Language, local tasks, bilingual/mixed-script competence and correct event time first. Strategy: Egyptian relevance and distinctiveness |
| 8 Automatic pyramids/pharaonic? | No; no national/heritage motif is automatically approved. Research: Egyptian locality |
| 9 Final logo chosen? | No; V1 mark is evidence only. Research opening/audit |
| 10 Final color chosen? | No palette or primary color selected. Research: Functional identity research criteria |
| 11 Final font chosen? | No; V1 bundled families are not V2 approval. Research audit/criteria |
| 12 Visual direction chosen? | No; six unranked hypotheses are not A/B/C winners. Research territories |
| 13 Next stage? | Independent research review, owner acceptance/health gate and separate authorization first; then materially distinct directions with bilingual/functional proof. Current status Next gate / exploration brief |
| 14 How many directions? | Exactly three, A/B/C. Brief: Inputs and objective |
| 15 Minimum logo concepts? | At least two materially different per direction, minimum six total; tiny variations fail. Brief: Logo exploration contract |
| 16 Can Codex choose winner? | No; Ahmed chooses/rejects/requests hybrid; recommendation non-binding. Brief: Evaluation and owner review format |
| 17 UI examples? | Patient desktop/mobile My care and Find care/appointment; Doctor desktop Schedule, active Consultation and meaningful mobile/responsive context; AR/EN and representative states. Brief: Representative UI required in every direction |
| 18 Copy competitors? | No copied mark/layout/whole palette/distinctive art/protected asset or near-clone; patterns only. Brief anti-clone constraints / map |
| 19 Owner decisions? | BR01–BR08 strategic bundles now; later explicit direction choice and final-brand approval. Decision register: Owner strategic decisions |
| 20 After direction choice? | Record selection/refinements, review coherent hybrid if applicable; refine, then separate Final Brand V2 approval, later Design System/prototypes/architecture/implementation/QA gates. Brief: Evaluation and owner review format |

The agent also checked accepted IA01–IA05, CD01–CD07, clinical/privacy semantics and future-Lab honesty: no brand-package contradiction found. It identified one stale SOURCE_OF_TRUTH IA index-cell phrase saying vocabulary was still proposed; this was corrected to accepted CD01–CD07 with historical working labels, including the adjacent sitemap entry; the same fresh agent performed a focused recheck and confirmed the finding resolved. No accepted contract or original adoption-time evidence was rewritten. This comprehension check is **not** native-user validation, strategic owner acceptance, legal clearance or the full independent Brand Research PR review.

## Whole-project health and next gate

Base main CI [41382337698](https://github.com/abuhmaid28/egyhealth360/actions/runs/41382337698) was observed SUCCESS for the exact base. Accepted health **B — HEALTHY WITH NON-BLOCKING DEBT** remains unchanged; no new P0/P1 foundation defect was established by this research. Existing [IA D01–D09 exposure gaps](INFORMATION_ARCHITECTURE.md#8-dependencies-and-capability-gaps), native/rendering/accessibility work, participant validation and pre-final deployment limitations remain. No runtime or hosting regression claim is inferred from docs-only checks.

Independent Brand Research review, explicit owner disposition of BR01–BR08/research acceptance, and the whole-project health checkpoint precede a separate start authorization for visual directions. Direction selection then leads to refinement and later Final Brand V2 approval, Design System and prototype gates. This package does not start any of those stages. No logos, UI designs or Design System V2 are generated.
